Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00118014|
Recruitment Status : Completed
First Posted : July 11, 2005
Last Update Posted : May 20, 2008
|Condition or disease||Intervention/treatment||Phase|
|Impulse Control Disorders||Drug: Sertraline Behavioral: Habit Reversal Training||Phase 4|
The purpose of this study is to assess the extent of symptom remission in patients with trichotillomania following treatment with sertraline and/or behavior therapy.
Following entry into the study, subjects will undergo a washout period if they are currently taking a psychotropic medication (two weeks for psychotropic medications except for fluoxetine, which requires a four-week washout). Subjects will then be given a single-blind placebo for two weeks and assessed for symptom consistency.
Subjects will take sertraline or placebo in a double-blind design. Subjects will be assessed with the Hamilton Rating Scale for Depression (HAM-D-17), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Clinical Global Impressions Scale (CGI), Hair Pulling Scale (HPS), Trichotillomania (TTM) Impact Scale, Psychiatric Institute Trichotillomania Scale (PITS), National Institute of Mental Health (NIMH) Scale, and Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) at the start of the washout period and at the end of week two in order to be randomized into the study. Subject randomization to a treatment arm will be based on the random table and in equal proportions.
Subject change scores will be assessed for the above scales, and change scores for the four different treatment groups will be assessed.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||75 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania|
|Study Start Date :||January 2000|
|Primary Completion Date :||April 2004|
|Study Completion Date :||August 2004|
- Clinical Global Impressions Scale change scores (week 2 versus 22) [ Time Frame: Week 2 to 22 ]
- Hair Pulling Scale change scores (week 0 versus 22) [ Time Frame: Week 0 to 22 ]
- TTM Impact Scale change scores (week 0 versus 22) [ Time Frame: Week 0 to 22 ]
- PITS (week 0 versus 22) [ Time Frame: Week 0 to 22 ]
- NIMH Scale (week 0 versus 22) [ Time Frame: Week 0 to 22 ]
- HAM-D-17 (week 0 versus 22) [ Time Frame: Week 0 to 22 ]
- BDI (week 0 versus 22) [ Time Frame: Week 0 to 22 ]
- BAI (week 0 versus 22) [ Time Frame: Week 0 to 22 ]
- Q-LES-Q (week 0 versus 22) [ Time Frame: Week 0 to 22 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00118014
|United States, Massachusetts|
|Massachusetts General Hospital - OCD Clinic|
|Charlestown, Massachusetts, United States, 02129|
|Principal Investigator:||Michael Jenike, M.D.||Massachusetts General Hospital|